GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021

GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021
News provided by
Share this article
Share this article
BOSTON, April 14, 2021 /PRNewswire/ -- GeneLeap Bio., a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an ePoster entitled 'Hydrogel encapsulated TLR9 agonists show sustained tumor growth inhibition and prolong survival of CT26 tumor-bearing mice' at the American Association for Cancer Research 2021 Annual Meeting. The preclinical study shows that compared with using TLR9 agonist on its own, a hydrogel encapsulated TLR9 agonist, independently developed by GeneLeap Biotech, can significantly improve antitumor performance, while demonstrating tumor growth inhibitory effects similar to that of TLR9 agonist without hydrogel encapsulation.

Related Keywords

United States ,Boston ,Massachusetts ,American ,Jason Zhang ,Sean Fu ,Geneleap Bio ,American Association For Cancer Research ,Luye Life Sciences ,American Association ,Cancer Research ,Geneleap Biotech ,ஒன்றுபட்டது மாநிலங்களில் ,போஸ்டன் ,மாசசூசெட்ஸ் ,அமெரிக்கன் ,ஜேசன் ஜாங் ,சீன் ஃபூ ,அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி ,லூயே வாழ்க்கை அறிவியல் ,அமெரிக்கன் சங்கம் ,புற்றுநோய் ஆராய்ச்சி ,